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Materials and methods. Two patients diagnosed and treated for gastric cancer 4 and 20 years before the onset of bone metastasis.
Both are man of 57 and 47 years old. In both cases the metastasis were multiple and initial clinical was spinal cord compression
(D11-L1 and D4), both operated (laminectomy and ﬁxation of fracture). Gastric origin was found on histology. Both these locations
receive radiotherapy after surgery (20Gy in 5 sessions) followed by chemotherapy.
Results and conclusion. Treatment outcome in both cases was wrong, not correct the neurological clinical and with short survival.
This presentation is described in young patients with a history of gastric cancer generally undifferentiated tumors with positive
nodes and types III and IV of Borrman. Usually are osteolytic metastases, but also there are described osteoblasts. Cases have
been reported after 4, 11 and 19 years of initial treatment and our 20 years is the furthest from the primary we know. Is some-
times associated with bone marrow involvement and disseminated intravascular coagulation (DIC). The prognosis is poor in the
short/medium term.
http://dx.doi.org/10.1016/j.rpor.2013.03.195
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Objectives. To investigate dosimetric predictors of Grade 3 or greater gastrointestinal (GI) toxicity during hypofractionated
intensity-modulated radiation therapy concomitant with capecitabine and oxaliplatin (IMRT-CAPOX) in patients with locally
advanced rectal cancer (LARC).
Patients and methods. Patients with diagnostic of T3–T4 and/or N0–N+ rectal cancer received Capecitabine 825mg/m2 twice
daily Monday through Friday and oxaliplatin 60mg/m2 intravenously on Days 1, 8, and 15, concurrently with IMRT
(47.5Gy/2.5Gy/fraction/20 fractions). All patients who underwent IMRT-CAPOX from March 2003 to July 2008 were analyzed.
Dose volume histograms (DVH) of the small bowel (SB), rectum and sphincter were individually recovered. Correlation between
dosimetric parameters (V5, V10, V15, V20, V25, V30, V35, V40, V45, V50, V55) from each organ and Grade 3 GI toxicity (diarrhea
and rectitis) was investigated using logistic regression. Best predictive cut-off values were assessed by ROC curves.
Results. 100 patients were analyzed. No Grade 4 toxicity was assessed. Grade 3 diarrhea was observed in 9 patients (9%), and
grade 3 rectitis in 11 patients (11%). No dose-volume predictors related to Grade 3 rectitis were found. V10, V15 and V50 of SB
were found to be dose-volume predictors of G3 diarrhea (p=0.01, p=0.02 and p=0.027, respectively) and the best cut-off value
for each volume was 92.6 cm3, 78.8 cm3 and 4.44 cm3 respectively.
Conclusion. Low doses to high volumes of SB, such a V10 and V15, seem to be predictors of G3 diarrhea in LARC patients treated
with hypofractionated IMRT-CAPOX protocol. We are currently using these constraints in our LARC patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.196
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Resumen
Background and aim. Neoadjuvant treatment with concurrent radiochemotherapy improves local control in locally advanced
rectal cancer, however its effect on survival outcomes is still controversial. In order to determinate the impact on survival of this
modality of treatment we have evaluated the correlation between the tumour response after preoperative treatment and survival
beneﬁt. Methods: We have reviewed the data from 108 patients with locally advanced rectal cancer (T3–4 N0 M0/Tx N1–2 M0). All
patients were treated preoperatively with concurrent radiotherapy and either raltitrexed (3mg/m2 days 1, 19, 38) or capecitabine
(825mg/m2 twice daily on days 1–38) based chemotherapy regimen. pTNM staging was evaluated in both regimens and tumour
regression grade (TRG) was measured using Dworak system that goes from TRG 0 to TRG 4 (complete regression).
Results. Tumour regression grade as follows: TRG 4, 6 patients (6.1%); TRG 3, 15 patients (15.3%); TRG 2, 57 patients (58,2%); TRG 1,
20 patients (20.4%). Down-staging after preoperatively treatment: 57 patients (58.2%). Signiﬁcant correlation was found between
tumour regression grade and survival, either overall and disease-free survival. Five-year disease-free survival was 100, 89.9, 66.7
and 33% in TRG 4, 3, 2, and 1, respectively (p<0.001). Five-year overall survival was 83.3, 89.9, 82.3 and 49.7%, respectively, in TRG
4, 3, 2 and 1 (p<0.001). Five-year cancer-speciﬁc survival was 100, 100, 78 and 44% in TRG 4, 3, 2 and 1, respectively.
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Conclusions. Tumour regression grade has a signiﬁcant impact on survival outcomes, which were lower in patients with poor
down-staging after neoadjuvant treatment. The use of a standardized system to evaluate tumour response in rectal cancer can
allow for comparisons between different institutions and can identify patients at worse prognosis to be treated with adjuvant
therapy. However, these results need further analysis with prospective studies.
http://dx.doi.org/10.1016/j.rpor.2013.03.197
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Background. Squamous cell cancer of the anus is an uncommon malignancy. The idea of organ preservation emerged following the
discovery of a high rates of complete response to combined chemoradiation prior to abdominal–perineal resection. Radiotherapy,
with concomitant chemotherapy for advanced tumours, is now the standard ﬁrst-line treatment for anal carcinoma.
Aim. The aim of this study was to retrospectively evaluate clinical characteristics, local control, and acute toxicity of patients
with anal canal carcinoma treated with radiation therapy. Methods: From 2004 to 2011, 16 patients with good performance status
(Karnofsky Performance status ≥70) were treated with radiation therapy at a single institution. The median age was 64 years
(range, 33–82 years). The TNM classiﬁcation was as follows: 2 stage I, 4 stage II, 4 stage III, 2 unknown and 4 recurrences. Patients
received either radiochemotherapy (N=12) or radiotherapy alone (N=6) consisting of a median delivered dose of 50Gy. Toxicity
was evaluated using the Radiation Therapy Oncology Group scale.
Results. With a median follow-up of 16 months (range, 23–47), there were 6 relapses (2 both regional and distant and 4 both
local-regional and distant). The main symptom at diagnosis was pain in the anal area (N=8) followed by rectal bleeding (N=6).
The most common acute grade 3 complication was radiation mucositis, which occurred in 6 cases (38%). In addition, ﬁve patients
experienced grade 2 acute proctitis and 5 grade 3 after radiation therapy. Only 3 patients showed grade 3 acute dermatitis being
grade 2 in 7 patients.
Conclusions. Radiation therapy appears to be an effective and well tolerated treatment for anal carcinoma offering both high local
tumor control and anal sphincter preservation.
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Introduction. The current treatment of anal canal cancer is concurrent radiotherapy and chemotherapy. Our new goal is to achieve
better local control rates without increasing secondary effects. The IMRT is a new path to follow to achieve this goal. OBJECTIVE:
To evaluate the outcomes and toxicity of patients with anal canal carcinoma treated with IMRT and simultaneous integrated
boost.
Method and materials. 9 patients with biopsy proved squamous cell carcinoma treated with IMRT with simultaneous integrated
boost were analyzed. Six of them were simulated with PET-CT, and all of them received concomitant chemotherapy. Treatment
volumes were macroscopic tumor and suspected malignant nodes as GTV, pelvic lymph nodes at risk including inguinal regions
as CTV; PTVs was created expanding CTVs by 0.5 cm. Dose schedule was 50.4Gy at 1.8Gy/day to tumor and lymph nodes at risk
and 60.48Gy in an integrated boost of 2.16Gy to visible tumor and malignant suspected lymph nodes. Treatment was completed
in 28 fractions. Megavoltage ConeBeam CT IGRT was performed in all patient.
Results. The mean age was 62 years (43–87). All patients received concomitant chemotherapy with mitomycin C and 5FU, except
an elderly patient who was treated with Xeloda Two patients had acute genitourinary toxicity (ctcae v3) GII. Six patients had
grade II skin toxicity, no toxicity greater than G-III was found. One patient developed G-III proctitis two years after treatment
completion and were treated with argon laser. One patient had a local recurrence one year after treatment and was surgically
rescued. Histopathological analysis showed the presence of adenocarcinoma instead of the initially proved squamous histology.
Conclusion. IMRT is well tolerated in patients with anal cancer and the use of integrated boost, do not seems to increase the acute
or chronic toxicity compared to historical series.
http://dx.doi.org/10.1016/j.rpor.2013.03.199
